Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Xenetic Biosciences Inc (XBIO)
Xenetic Biosciences Inc (XBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,824
  • Shares Outstanding, K 1,541
  • Annual Sales, $ 1,710 K
  • Annual Income, $ -6,550 K
  • 60-Month Beta 2.63
  • Price/Sales 2.44
  • Price/Cash Flow N/A
  • Price/Book 0.54
Trade XBIO with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 65.02%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.87
  • Number of Estimates 1
  • High Estimate -0.87
  • Low Estimate -0.87
  • Prior Year -1.00
  • Growth Rate Est. (year over year) +13.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.07 +23.13%
on 01/24/24
4.15 -8.90%
on 02/07/24
+0.31 (+8.78%)
since 01/19/24
3-Month
3.00 +26.06%
on 11/28/23
4.32 -12.59%
on 12/07/23
+0.57 (+17.63%)
since 11/21/23
52-Week
2.55 +48.24%
on 05/18/23
5.99 -36.89%
on 02/23/23
-1.86 (-32.98%)
since 02/21/23

Most Recent Stories

More News
Xenetic Biosciences: Q3 Earnings Snapshot

Xenetic Biosciences: Q3 Earnings Snapshot

XBIO : 3.78 (-1.91%)
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

FRAMINGHAM, MA / ACCESSWIRE / November 10, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies...

XBIO : 3.78 (-1.91%)
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

EVFM : 0.0270 (-15.63%)
GRI : 0.9600 (-1.03%)
MBRX : 0.5012 (+0.28%)
XBIO : 3.78 (-1.91%)
AREC : 1.3100 (-7.09%)
CNSP : 0.2863 (-1.28%)
NVNO : 5.32 (-3.62%)
PALI : 0.4290 (-2.50%)
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ET

XBIO : 3.78 (-1.91%)
Xenetic Biosciences: Q2 Earnings Snapshot

Xenetic Biosciences: Q2 Earnings Snapshot

XBIO : 3.78 (-1.91%)
Xenetic Biosciences: Q1 Earnings Snapshot

Xenetic Biosciences: Q1 Earnings Snapshot

XBIO : 3.78 (-1.91%)
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -21.54% and 15.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ESPR : 2.61 (-2.61%)
XBIO : 3.78 (-1.91%)
Collegium Pharmaceutical (COLL) Q1 Earnings Meet Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

COLL : 31.76 (-1.00%)
XBIO : 3.78 (-1.91%)
Journey Medical Corporation (DERM) Reports Q3 Loss, Misses Revenue Estimates

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -67.65% and 11.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

DERM : 3.76 (+0.80%)
XBIO : 3.78 (-1.91%)
Xenetic Biosciences: Q3 Earnings Snapshot

Xenetic Biosciences: Q3 Earnings Snapshot

XBIO : 3.78 (-1.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an...

See More

Key Turning Points

3rd Resistance Point 3.92
2nd Resistance Point 3.85
1st Resistance Point 3.82
Last Price 3.78
1st Support Level 3.72
2nd Support Level 3.65
3rd Support Level 3.62

See More

52-Week High 5.99
Fibonacci 61.8% 4.68
Fibonacci 50% 4.27
Fibonacci 38.2% 3.86
Last Price 3.78
52-Week Low 2.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar